A 2026 retrospective study in Lasers in Surgery and Medicine adds to growing evidence that photobiomodulation therapy (PBMT) can improve sensory recovery in patients with inferior alveolar nerve injuries after oral surgery. As of August 2026, PBMT is gaining traction as a noninvasive treatment option for one of dentistry's most frustrating complications — and Canadian dentists should understand what the evidence supports and where the gaps remain.
As of August 2026, inferior alveolar nerve (IAN) injury remains one of the most consequential complications in oral and maxillofacial surgery. Whether the injury occurs during third molar extraction, implant placement, orthognathic surgery, or endodontic procedures, the result — persistent numbness, tingling, or pain in the lower lip, chin, and gums — can profoundly affect a patient's quality of life. For the treating dentist, it can also mean difficult conversations, extended follow-up, and potential medico-legal exposure.
Traditional management has relied heavily on watchful waiting, with most clinicians advising patients that sensation may return gradually over 6 to 18 months. Microsurgical nerve repair exists as an option for severe cases, but it requires specialized referral, carries its own risks, and is not widely available across Canada. This is why the growing body of evidence around photobiomodulation therapy — commonly known as low-level laser therapy (LLLT) — is attracting serious clinical attention.
What the 2026 Study Found
The retrospective study published in Lasers in Surgery and Medicine in 2026, authored by Ates and colleagues, evaluated clinical outcomes of a PBMT protocol in 55 patients (66 affected nerve sides) with IAN injury following various oral and maxillofacial procedures. The researchers specifically investigated three variables: the etiology of the nerve injury, the time elapsed before treatment initiation, and the total number of PBMT sessions administered.
The study population included 39 females and 16 males with a mean age of 35.69 years (range 15–80). This demographic distribution reflects a common clinical reality: third molar extractions and implant procedures — the most frequent causes of IAN injury — are performed across a wide age range, with younger patients overrepresented in the wisdom tooth extraction cohort.
While the full results require careful interpretation given the retrospective design, the study contributes to a broader literature suggesting that PBMT, when applied with appropriate parameters, may accelerate neurosensory recovery and reduce the duration of patient-reported symptoms.
Pro Tip: If you are considering incorporating PBMT into your practice's post-operative protocol, document your laser parameters meticulously — wavelength, power density, energy density, treatment duration, and number of sessions. This documentation is critical for both clinical follow-up and for contributing meaningful data to the evidence base.
How Photobiomodulation Works at the Cellular Level
Photobiomodulation therapy uses specific wavelengths of light — typically in the red (630–660 nm) and near-infrared (800–1,100 nm) range — to stimulate cellular processes without generating thermal effects. The primary mechanism involves the absorption of photons by cytochrome c oxidase, a key enzyme in the mitochondrial electron transport chain. This absorption enhances ATP production, modulates reactive oxygen species, and activates transcription factors that promote cell proliferation, anti-inflammatory responses, and neural repair.
For nerve injuries specifically, the proposed benefits include enhanced Schwann cell proliferation (essential for peripheral nerve regeneration), reduced neuroinflammation, and promotion of axonal regrowth. Animal studies have demonstrated these effects at a histological level, with dual-wavelength protocols showing particular promise in rat models of IAN injury.
Clinical Evidence: What We Know and What We Do Not
The evidence base for PBMT in dental nerve injury management has been building steadily. A systematic review and meta-analysis published in recent years evaluated PBMT efficacy across studies involving IAN injuries from orthognathic surgery, third molar extraction, and mandibular fracture management. The pooled findings generally favoured PBMT over no treatment or sham laser for subjective sensory improvement, though the heterogeneity of protocols — different wavelengths, power outputs, treatment frequencies, and outcome measures — makes definitive conclusions challenging.
What the literature consistently suggests is that timing matters. Patients who begin PBMT within the first three months following nerve injury appear to respond more favourably than those who start treatment after a prolonged delay. The 2026 Ates study specifically examined this variable, providing further data on the relationship between treatment initiation timing and clinical outcomes.
However, several important caveats apply. The majority of published studies are retrospective or use small sample sizes. Randomized controlled trials with standardized protocols and long-term follow-up remain limited. The lack of consensus on optimal treatment parameters — including wavelength, energy density, application technique, and total number of sessions — makes it difficult to establish universally accepted clinical guidelines.
Pro Tip: When discussing PBMT with patients who have sustained an IAN injury, frame it accurately: a noninvasive adjunctive therapy with a growing but not yet definitive evidence base. Avoid promising specific timelines for recovery or guaranteed outcomes. Document the informed consent discussion.
Relevance for Canadian Dental Practices
For dentists practising in Ontario and across Canada, the emergence of PBMT as a management tool for IAN injury raises several practical considerations.
First, the Royal College of Dental Surgeons of Ontario (RCDSO) requires that any therapeutic modality used in a dental practice be supported by reasonable evidence and applied within the practitioner's scope of competence. Dentists who already own diode lasers for soft tissue procedures may find that their existing equipment can be configured for PBMT protocols, though additional training specific to neurosensory applications is advisable.
Second, provincial dental fee guides do not currently include specific billing codes for PBMT in the context of nerve injury management. Practitioners offering this treatment would typically bill under laser therapy codes or as part of a comprehensive post-operative management plan. The Canadian Dental Association (CDA) has not issued specific guidelines on PBMT for nerve injuries as of August 2026, though it recognizes laser therapy as a legitimate modality within dental practice.
Third, the medico-legal implications of IAN injury make it essential to establish clear protocols. If your practice plans to offer PBMT as an adjunctive treatment following nerve injury, establish a written protocol that includes patient selection criteria, treatment parameters, outcome tracking, and referral thresholds for cases that do not respond within an expected timeframe.
Where PBMT Fits in the Treatment Algorithm
PBMT is not positioned as a replacement for established management approaches. Rather, it adds a noninvasive layer to the treatment algorithm for IAN injury:
- Immediate post-injury (0–3 months): Observation, patient reassurance, pharmacological management of neuropathic pain if present. PBMT may be initiated during this phase based on the emerging evidence favouring early intervention.
- Intermediate phase (3–6 months): If sensory deficits persist, continued PBMT along with assessment for possible microsurgical referral. The window for surgical intervention begins to narrow after 6–12 months.
- Chronic phase (6+ months): For patients with persistent deficits, PBMT may still offer some benefit, though the evidence for late-stage intervention is weaker. At this point, referral to an oral and maxillofacial surgery centre with microsurgical capability (such as those affiliated with the University of Toronto Faculty of Dentistry or Sunnybrook Health Sciences Centre) should be strongly considered.
Equipment Considerations
Not all dental lasers are appropriate for PBMT. The key distinction is between high-power surgical lasers (which cut tissue through photothermal effects) and low-level therapeutic lasers (which deliver sub-thermal doses of light energy). For PBMT in nerve injury applications, devices operating in the near-infrared range (typically 808 nm, 830 nm, or 980 nm) at low power densities are used. Several manufacturers offer diode laser units that include both surgical and therapeutic modes, making them versatile additions to a Canadian dental practice.
When evaluating equipment, confirm that the device has Health Canada medical device licensure. Products that carry only FDA clearance for the US market may not be legally marketable in Canada. The Medical Devices Active Licence Listing (MDALL) database maintained by Health Canada is the definitive resource for confirming device registration in Canada.
Pro Tip: Before purchasing a new laser unit, contact the manufacturer to request their PBMT-specific protocol documentation for nerve injury applications. A reputable manufacturer should be able to provide peer-reviewed references supporting their recommended parameters, not just marketing materials.
The Broader Picture: Laser Therapy in Dentistry Is Expanding
The interest in PBMT for nerve injuries sits within a broader trend of laser therapy adoption across dental specialties. From photobiomodulation for temporomandibular disorder (TMD) pain to accelerated orthodontic tooth movement and post-surgical healing, the applications continue to grow. The 2026 research landscape reflects this expansion, with studies exploring PBMT for conditions including oral mucositis, implant osseointegration, and chronic orofacial pain syndromes.
For Canadian dental practices considering a laser investment, the potential to apply the same device across multiple clinical indications strengthens the business case. A diode laser that serves soft tissue surgery, PBMT, and potentially teeth whitening represents a more compelling return on investment than a single-purpose instrument.
What to Watch in 2026 and Beyond
Several developments could shape the trajectory of PBMT in dentistry over the next 12 to 24 months:
- Standardized protocols: The push toward consensus guidelines for PBMT parameters in specific dental applications is gaining momentum within professional organizations and laser medicine societies.
- Larger clinical trials: Multi-centre randomized controlled trials with longer follow-up periods are needed — and some are reportedly in progress — to move PBMT from "promising" to "evidence-based" for IAN injury management.
- Insurance recognition: As the evidence base matures, there may be movement toward dedicated billing codes and insurance coverage for PBMT in both Canadian provincial fee guides and private dental insurance plans.
- AI-assisted treatment planning: Emerging platforms that combine diagnostic imaging with AI analysis may eventually help predict which patients are most likely to respond to PBMT based on injury characteristics and timing.
Frequently Asked Questions
Q: Is photobiomodulation therapy the same as low-level laser therapy?
Yes, photobiomodulation therapy (PBMT) and low-level laser therapy (LLLT) refer to the same treatment approach. The term PBMT is now preferred in the scientific literature because it more accurately describes the mechanism — modulation of biological processes through light — and avoids confusion with high-power surgical laser applications that are fundamentally different in their tissue effects.
Q: How many PBMT sessions are typically needed for dental nerve injuries?
Published protocols vary, but most studies report treatment courses of 10 to 20 sessions delivered over 4 to 8 weeks, with sessions occurring two to three times per week. The 2026 Ates study specifically examined whether the number of sessions correlated with clinical outcomes. Practitioners should establish clear treatment milestones and reassess progress at regular intervals rather than committing to a fixed number of sessions upfront.
Q: Can any dentist in Ontario perform PBMT, or does it require special certification?
As of August 2026, the RCDSO does not require a separate certification or specialty designation to perform PBMT. However, the College expects that any dentist using laser therapy does so within their scope of competence, which means obtaining appropriate training in laser physics, safety, and clinical application. Several continuing education providers and laser manufacturers offer accredited PBMT training courses that satisfy this expectation. Dentists should maintain documentation of their training for regulatory compliance.
EBIKO Dental will continue monitoring developments in photobiomodulation therapy research and their implications for Canadian dental practices.